Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of “Hold” from Analysts

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been given a consensus recommendation of “Hold” by the six research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $5.00.

Separately, Wells Fargo & Company began coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price objective for the company.

Zentalis Pharmaceuticals Stock Performance

Zentalis Pharmaceuticals stock opened at $2.53 on Thursday. The company has a market cap of $182.79 million, a P/E ratio of -1.22 and a beta of 1.71. Zentalis Pharmaceuticals has a one year low of $1.01 and a one year high of $3.95. The business has a fifty day moving average of $2.63 and a two-hundred day moving average of $1.92.

Insider Activity

In other Zentalis Pharmaceuticals news, insider Vincent Vultaggio sold 29,951 shares of the stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $2.43, for a total value of $72,780.93. Following the completion of the transaction, the insider directly owned 156,779 shares of the company’s stock, valued at approximately $380,972.97. This trade represents a 16.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Group Walters purchased 6,459,973 shares of Zentalis Pharmaceuticals stock in a transaction dated Wednesday, December 31st. The shares were bought at an average price of $1.20 per share, with a total value of $7,751,967.60. Following the completion of the transaction, the insider owned 13,509,973 shares in the company, valued at approximately $16,211,967.60. This trade represents a 91.63% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 46,617 shares of company stock worth $113,417 over the last 90 days. 1.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ZNTL. Sivia Capital Partners LLC purchased a new stake in Zentalis Pharmaceuticals during the fourth quarter worth $27,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Zentalis Pharmaceuticals in the second quarter valued at $31,000. Voleon Capital Management LP purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at $41,000. SG Americas Securities LLC raised its stake in shares of Zentalis Pharmaceuticals by 35.3% during the 3rd quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock worth $48,000 after buying an additional 8,236 shares during the last quarter. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth $37,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.